Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study

Sponsor
Kasr El Aini Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04306913
Collaborator
(none)
80
1
2
5
15.9

Study Details

Study Description

Brief Summary

Perioperative myocardial injury remains one of the most serious complications of cardiac surgery.

Numerous factors have been implicated during the pathogenesis process, including the technique of cardiac surgery, induction of cardioplegia and period of cardiac arrest.

Lactic acid is the normal endpoint of the anaerobic breakdown of glucose in the tissues. The lactate exits the cells and is transported to the liver, thus it's considered to be an indicator of ischemia as it is produced by most tissues in the human body, with the highest level of production found in muscle.

In any cardiac valve replacement surgery, patient must undergo cardiac bypass and arrest in diastole by using hyperkalemic cardioplegia solution; meanwhile the metabolism of myocardial cells is purely anaerobic.

Esmolol an ultra-short beta blocker is supposed to decrease the anaerobic insult to the myocardial cells.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Prevention
Official Title:
Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study
Anticipated Study Start Date :
Apr 1, 2020
Anticipated Primary Completion Date :
Sep 1, 2020
Anticipated Study Completion Date :
Sep 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control

Drug: Potassium Cardioplegic Solution
15 meq potassium added to cardioplegia solution

Experimental: Esmolol

Drug: Esmolol
esmolol 250 mg in cardioplegia solution every 25 minutes

Drug: Potassium Cardioplegic Solution
15 meq potassium added to cardioplegia solution

Outcome Measures

Primary Outcome Measures

  1. Coronary sinus lactate level immediately before declamping the aorta. [1 hour during declamping]

    the lactate from the coronary sinus

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 20-50 years old patients, with either sex with solitary valvular disease
Exclusion Criteria:
  • • Myocardial infarction within 2 weeks.

  • History of reaction or toxicity to esmolol or other beta blockers.

  • New York Heart Association class IV congestive heart failure despite treatment.

  • Persistent hypotension (systolic blood pressure <80 mm Hg).

  • severe pulmonary hypertension

  • Ejection fraction less than 45%

  • Patients with coronary artery disease

  • Patients with congenital heart disease

  • Patients with previous cardiac surgery

  • Patients with liver disease (child class B and C)

  • Patients with second or third degree heart block

  • Patients having resting heart rate less than 50 ppm

  • Patients using calcium channel blockers

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kasr alainy medical school Cairo Egypt 12566

Sponsors and Collaborators

  • Kasr El Aini Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ayman Abougabal, Consultant, Kasr El Aini Hospital
ClinicalTrials.gov Identifier:
NCT04306913
Other Study ID Numbers:
  • D-47-2019
First Posted:
Mar 13, 2020
Last Update Posted:
Mar 13, 2020
Last Verified:
Mar 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 13, 2020